title: Treatment options for pyoderma gangrenosum.
abstract: Pyoderma gangrenosum (PG) is an orphan disease. While research on such disorders is based on only few randomized multicenter as well as retrospective studies, most of the data comes from case series of small patient groups. Apart from topical and intralesional therapeutic options for early stages and mild disease courses, treatment predominantly involves systemic therapeutic agents. Besides systemic corticosteroids and cyclosporine A (CsA), options also include intravenous immunoglobulins (IVIG) and biologics such as the TNFα inhibitors infliximab, adalimumab, and etanercept; the interleukin (IL) 12/23 antibody ustekinumab; the IL-1 receptor antagonist anakinra; and the IL-1β antibody canakinumab. The best evidence-based study data is available for CsA, prednisolone, and infliximab; the latter especially in patients with concomitant ulcerative colitis or Crohn's disease. A response to IVIG and canakinumab has been reported in smaller case series. First described by Brocq almost 100 years ago, it was soon recognized that PG did in fact require treatment. To this day, however, such treatment remains a clinical challenge. Despite the severe - albeit rare -clinical picture, improvement in therapeutic options may be expected in the future, primarily due to further clinical studies - especially with a greater number of patients, a better understanding of the etiopathogenesis, as well as the use of modern targeted therapies with higher efficacy and a lower rate of side effects than conventional immunosuppressants such as prednisolone and CsA.
authors.affiliation: Department of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany.
authors.forename: Sven R
authors.initials: SR
authors.lastname: Quist
authors.affiliation: Department of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany.
authors.forename: Luise
authors.initials: L
authors.lastname: Kraas
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D015552:Injections, Intralesional; D015337:Multicenter Studies as Topic; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D035583:Rare Diseases; D012189:Retrospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D001688:Biological Products; D007166:Immunosuppressive Agents; D016572:Cyclosporine